Novo Nordisk's weight-loss drug Wegovy approved by UK drug pricing regulator for heart disease, expanding eligible population by 1.2 million
England's drug pricing regulator has recommended Novo Nordisk's weight-loss drug Wegovy for the prevention of heart attacks and strokes. The new recommendation from the National Institute for Health and Care Excellence (NICE) will significantly expand Wegovy's coverage within the country's National Health Service (NHS), with NICE deeming that approximately 1.2 million people could be eligible to use the drug to help prevent further heart attacks or strokes as it is used for this condition. Novo Nordisk's stock, listed in Copenhagen, rose as much as 4% on Wednesday.
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments